ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$2.40
-0.03 (-1.23%)
Open$2.43
Previous Close$2.43
Day High$2.45
Day Low$2.38
52W High$7.08
52W Low$2.04
Volume—
Avg Volume679.5K
Market Cap313.97M
P/E Ratio115.47
EPS$-0.02
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+247.9% upside
Current
$2.40
$2.40
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 557.35M | 517.22M | 163.70M |
| Net Income | 36.58M | 30.55M | 15.03M |
| Profit Margin | 6.6% | 6.2% | 9.2% |
| EBITDA | 59.24M | 52.23M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +7.8% | +7.8% | +17.3% |
| Debt/Equity | 0.05 | 0.05 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |